Skip to main content
Journal cover image

Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.

Publication ,  Journal Article
Pritchard, JE; Wilson, LE; Miller, SM; Greiner, MA; Cohen, HJ; Kaye, DR; Zhang, T; Dinan, MA
Published in: J Am Geriatr Soc
August 2022

BACKGROUND: Kidney cancer is the fastest-growing cancer diagnosis in the developed world. About 16% of new cases are stage IV, which has a low five-year survival rate. Many patients with metastatic renal cell carcinoma (mRCC) are older and may have mild cognitive impairment or dementia (MCI/D). Given prior reports of patients with dementia initiating less cancer therapy and the importance of oral anticancer agents (OAAs) in mRCC treatment, we investigated the prevalence of preexisting MCI/D in patients with mRCC and their OAA use. METHODS: SEER-Medicare patients were analyzed who were ≥65 years, diagnosed with mRCC between 2007 and 2015, and had Medicare part D coverage. Patterns and predictors of (a) OAA utilization within the 12 months following mRCC diagnosis and (b) adherence (percent of days covered [PDC] ≥ 80%) during the first 90 days following treatment initiation were assessed. RESULTS: Of the 2792 eligible patients, 268 had preexisting MCI/D, and 907 initiated OAA treatment within 12 months of mRCC diagnosis. Patients with preexisting MCI/D were less likely to begin an OAA than those without MCI/D (fully-adjusted HR 0.53, 95% CI 0.38-0.76). Among OAA initiators, a preexisting MCI/D diagnosis did not alter the likelihood that a person would be adherent (adjusted RR 0.84, 95% CI 0.55-1.28). CONCLUSIONS: Patients with preexisting MCI/D were half as likely to start an OAA during the year following mRCC diagnosis than patients without comorbid MCI/D. The 90-day adherence of OAA initiators was not significantly different between those with and without preexisting MCI/D. In light of this, clinicians should assess mRCC patients for cognitive impairment and take steps to optimize OAA utilization by those with MCI/D.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Geriatr Soc

DOI

EISSN

1532-5415

Publication Date

August 2022

Volume

70

Issue

8

Start / End Page

2330 / 2343

Location

United States

Related Subject Headings

  • United States
  • Medicare Part D
  • Kidney Neoplasms
  • Humans
  • Geriatrics
  • Dementia
  • Cognitive Dysfunction
  • Carcinoma, Renal Cell
  • Antineoplastic Agents
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pritchard, J. E., Wilson, L. E., Miller, S. M., Greiner, M. A., Cohen, H. J., Kaye, D. R., … Dinan, M. A. (2022). Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. J Am Geriatr Soc, 70(8), 2330–2343. https://doi.org/10.1111/jgs.17826
Pritchard, Jessica E., Lauren E. Wilson, Samuel M. Miller, Melissa A. Greiner, Harvey Jay Cohen, Deborah R. Kaye, Tian Zhang, and Michaela A. Dinan. “Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.J Am Geriatr Soc 70, no. 8 (August 2022): 2330–43. https://doi.org/10.1111/jgs.17826.
Pritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, et al. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. J Am Geriatr Soc. 2022 Aug;70(8):2330–43.
Pritchard, Jessica E., et al. “Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.J Am Geriatr Soc, vol. 70, no. 8, Aug. 2022, pp. 2330–43. Pubmed, doi:10.1111/jgs.17826.
Pritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, Zhang T, Dinan MA. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. J Am Geriatr Soc. 2022 Aug;70(8):2330–2343.
Journal cover image

Published In

J Am Geriatr Soc

DOI

EISSN

1532-5415

Publication Date

August 2022

Volume

70

Issue

8

Start / End Page

2330 / 2343

Location

United States

Related Subject Headings

  • United States
  • Medicare Part D
  • Kidney Neoplasms
  • Humans
  • Geriatrics
  • Dementia
  • Cognitive Dysfunction
  • Carcinoma, Renal Cell
  • Antineoplastic Agents
  • Aged